Extensive interest in cancer immunotherapy is reported according to the clinical importance of CTLA-4 and PD-1/PD-L1 [programmed death (PD) and programmed death-ligand (PD-L1)] in immune checkpoint therapies (43). Here, CD274 is linked to cancer.